Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Convertible Debt (2020 - 2025)

BridgeBio Pharma's Convertible Debt history spans 6 years, with the latest figure at $739.9 million for Q2 2025.

  • For Q2 2025, Convertible Debt changed 0.27% year-over-year to $739.9 million; the TTM value through Jun 2025 reached $739.9 million, changed 0.27%, while the annual FY2024 figure was $545.2 million, 0.33% changed from the prior year.
  • Convertible Debt for Q2 2025 was $739.9 million at BridgeBio Pharma, roughly flat from $739.4 million in the prior quarter.
  • Across five years, Convertible Debt topped out at $739.9 million in Q2 2025 and bottomed at $538.7 million in Q1 2021.
  • The 5-year median for Convertible Debt is $639.1 million (2021), against an average of $639.1 million.
  • The largest annual shift saw Convertible Debt skyrocketed 91.2% in 2021 before it dropped 26.09% in 2023.
  • A 5-year view of Convertible Debt shows it stood at $733.1 million in 2021, then grew by 0.25% to $735.0 million in 2022, then dropped by 26.07% to $543.4 million in 2023, then rose by 0.33% to $545.2 million in 2024, then surged by 35.71% to $739.9 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Convertible Debt are $739.9 million (Q2 2025), $739.4 million (Q1 2025), and $545.2 million (Q4 2024).